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A B S T R A C T
Background
Osteoarthritis is a chronic joint disease that involves degeneration of articular cartilage. Pre-clinical data suggest that doxycycline might
act as a disease-modifying agent for the treatment of osteoarthritis, with the potential to slow cartilage degeneration.
Objectives
To examine the effects of doxycycline compared with placebo or no intervention on pain and function in patients with osteoarthritis
of the hip or knee.
Search strategy
We searched CENTRAL (The Cochrane Library 2008, issue 3), MEDLINE, EMBASE and CINAHL up to 28 July 2008, checked
conference proceedings, reference lists, and contacted authors.
Selection criteria
We included studies if they were randomised or quasi-randomised controlled trials that compared doxycycline at any dosage and any
formulation with placebo or no intervention in patients with osteoarthritis of the knee or hip.
Data collection and analysis
We extracted data in duplicate. We contacted investigators to obtain missing outcome information. We calculated differences in means
at follow-up between experimental and control groups for continuous outcomes and risk ratios for binary outcomes.
Main results
We found one randomised controlled trial that compared doxycycline with placebo in 431 obese women. After 30 months of treatment,
clinical outcomes were similar between the two treatment groups, with a mean difference of -0.20 cm (95% confidence interval (CI)
-0.77 to 0.37 cm) on a visual analogue scale from 0 to 10 cm for pain and -1.10 units (95% CI -3.86 to 1.66) for function on the
WOMAC disability subscale, which ranges from 17 to 85. These differences correspond to clinically irrelevant effect sizes of -0.08 and
-0.09 standard deviation units for pain and function, respectively. The difference in changes in minimum joint space narrowing was
in favour of doxycycline (-0.15 mm, 95% CI -0.28 to -0.02 mm), which corresponds to a small effect size of -0.23 standard deviation
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units. More patients withdrew from the doxycycline group compared with placebo due to adverse events (risk ratio 1.69, 95% CI 1.03
to 2.75).
Authors’ conclusions
The symptomatic benefit of doxycycline isminimal to non-existent. The small benefit in terms of joint space narrowing is of questionable
clinical relevance and outweighed by safety problems. Doxycycline should not be recommended for the treatment of osteoarthritis of
the knee or hip.
P L A I N L A N G U A G E S U M M A R Y
Doxycycline for osteoarthritis
This summary of a Cochrane review presents what we know from research about the effect of doxycycline on osteoarthritis.
The review shows that in people with osteoarthritis:
- Doxycycline probably will not improve pain or physical function.
- Doxycycline probably causes side effects. We often do not have precise information about side effects and complications. This is
particularly true for rare but serious side effects.
What is osteoarthritis and what is doxycycline?
Osteoarthritis (OA) is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try and repair
the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can
become misshapen and make the joint painful and unstable. This can affect your physical function or ability to use your knee.
Doxycycline is a type of antibiotic that seems to stop the process of damage to the joints. It is taken in pill form.
Best estimate of what happens to people with osteoarthritis who take doxycycline:
Pain
- People with doxycycline and people with placebo are equally likely to respond to treatment (difference of 0%).
- People who took doxycycline rated their pain to be 2 on a scale of 0 (no pain) to 10 (extreme pain) after 30 months.
- People who took a fake medication (placebo) also rated their pain to be about 2 on a scale of 0 (no pain) to 10 (extreme pain) after
30 months.
Physical function
- People with doxycycline and people with placebo are equally likely to respond to treatment (difference of 0%).
- People who took doxycycline rated their physical function to be about 36 on a scale of 17 (no disability) to 85 (extreme disability)
after 30 months.
- People who took a fake medication rated their physical function to be about 37 on a scale of 17 (no disability) to 85 (extreme disability)
after 30 months.
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Side effects
- 7 more people who took doxycycline withdrew or dropped out from the trial because of side effects (absolute difference of 7%).
- 17 people out of 100 who took doxycycline withdrew or dropped out from the trial because of side effects (17%).
- 10 people out of 100 who used a fake medication withdrew or dropped out from the trial because of side effects (10%).
Serious harms
- There was no difference in the number of people who experienced serious harms (difference of 0%). This could be the result of chance.
- 14 people out of 100 who took doxycycline experienced serious harms (14%)
- 14 people out of 100 who used a fake medication experienced serious harms (14%).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [ Explanation]
Doxycycline compared with placebo for osteoarthritis of the knee or hip
Patient or population: Patients with osteoarthritis of the knee or hip
Settings: Clinical Research Centres
Intervention: Doxycycline
Comparison: Placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk1 Corresponding risk
Placebo Doxycycline
Pain
10 cm VAS scale
(follow-up: 30 months)
2.2 cm pain
on 10 cm VAS
2.0 cm pain
(1 -0.2 cm, -0.8 to +0.4
cm)
307
(1)
++OO
low2
Little evidence of beneficial
effect (NNT: not statistically
significant)
Function
WOMAC function (range 17
to 85)
(follow-up: 30 months)
37.4 units on WOMAC
(range 17 to 85)
36.3 units on WOMAC
(1 -1.1, -3.9 to +1.7)
307
(1)
++OO
low2
Little evidence of beneficial
effect (NNT: not statistically
significant)
Minimum joint space
width
(follow-up: 30 months)
-45 mm change -30 mm change
(1 15 mm, 2 to 28 mm)
361
(1)
+++O
moderate3
No reasonable assumption
could be made for the cal-
culation of NNT
Number of patients with-
drawn due to adverse
events
(follow-up: 30 months)
103 per 1000 174 per 1000
(106 to 283)
RR 1.69 (1.03 to 2.75) 431
(1)
+++O
moderate3
NNH: 14 (95% CI 6 to 324)
Number of patients expe-
riencing any serious ad-
verse event
(follow-up: 30 months)
136 per 1000 141 per 1000
(88 to 227)
RR 1.04 (0.65 to 1.67) 431
(1)
++OO
low4
Little evidence of harmful
effect (NNH: not statistically
significant)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio; GRADE: GRADE Working Group grades of evidence (see explanations); NNT: number needed to treat; NNH: number needed to harm
GRADE Working Group grades of evidence
High quality (++++): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (+++O): Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality (++OO): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely
to change the estimate.
Very low quality (+OOO): We are very uncertain about the estimate.
1 Scores for efficacy outcomes and risks for safety outcomes from the placebo group in the trial.
2 Downgraded (2 levels) because the effect was estimated from a single trial, confidence intervals were wide and crossed no difference,
and the analyses were not done according to the intention-to-treat principle.
3 Downgraded (1 level) because the effect was estimated from a single trial.
4 Downgraded (2 levels) because the effect was estimated from a single trial, confidence intervals were wide and crossed no difference.
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B A C K G R O U N D
Osteoarthritis is a chronic joint disease that involves degeneration
of the articular cartilage. Doxycycline is a tetracycline antibiotic
which has been shown to induce inhibition of cartilage matrix
metallo-proteinases (MMPs) and to slow down the progression
of structural damage to the affected joint (Shlopov 1999; Smith
1996).Doxycycline was therefore suggested as a disease-modifying
agent for the treatment of osteoarthritis. Treatmentwith oral doxy-
cycline may slow down the rate of joint space narrowing, which
is used as a surrogate measure for cartilage loss of the knee in pa-
tients with knee osteoarthritis (Brandt 2005). However, treatment
benefits of putative chondro-protective disease-modifying agents
are still controversial. Chondroitin and glucosamine are other po-
tentially structure-modifying pharmacological substances that are
widely used to reduce the symptoms of osteoarthritis of the hip
or knee. Recently published meta-analyses, however, have ques-
tioned their effectiveness because of large heterogeneity between
studies and biases introduced by industry sponsored, methodolog-
ically weak and small trials (Reichenbach 2007; Vlad 2007). As
a tetracycline antibiotic, doxycycline interferes with various bio-
logical pathways and has effects on tissues other than cartilage (
Rubin 2000). Safety concerns about the long-term use of doxycy-
cline have also been expressed, especially in elderly patients with
co-morbid conditions (Dieppe 2005).
O B J E C T I V E S
We set out to compare doxycycline with placebo or no specific
intervention in patients with knee or hip osteoarthritis in terms of
effects on pain, function and safety outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials with a control
group receiving placebo or no intervention.
Types of participants
Studies including at least 75% of patients with clinically and/or
radiologically confirmed osteoarthritis of the knee or hip.
Types of interventions
Trials investigating doxycycline at any dosage and in any formula-
tion. Eligible control interventions were placebo or no interven-
tion.
Types of outcome measures
Primary outcomes
Main outcomes were pain and function, as currently recom-
mended for osteoarthritis trials (Altman 1996; Pham 2004). If
data on more than one pain scale were provided for a trial, we
referred to a previously described hierarchy of pain-related out-
comes (Juni 2006; Reichenbach 2007) and extracted data on the
pain scale that was highest on this list.
1. Global pain
2. Pain on walking
3. WOMAC osteoarthritis index pain subscore
4. Composite pain scores other than WOMAC
5. Pain on activities other than walking
6. Rest pain or pain during the night
7. WOMAC global algofunctional score
8. Lequesne osteoarthritis index global score
9. Other algofunctional scale
10. Patient’s global assessment
11. Physician’s global assessment
If data on more than one function scale were provided for a trial,
we extracted data according to the hierarchy presented below.
1. Global disability score
2. Walking disability
3. WOMAC disability subscore
4. Composite disability scores other than WOMAC
5. Disability other than walking
6. WOMAC global scale
7. Lequesne osteoarthritis index global score
8. Other algofunctional scale
9. Patient’s global assessment
10. Physician’s global assessment
If pain or function outcomes were reported at several time points,
we extracted themeasure at the end of the trial or at a maximum of
three months after termination of therapy, whichever came first.
Secondary outcomes
Secondary outcomes were minimum and mean radiographic joint
space width, the number of patients experiencing any adverse
event, patients who withdrew because of adverse events, and pa-
tients experiencing any serious adverse events. We defined seri-
ous adverse events as events resulting in in-patient hospitalisation,
prolongation of hospitalisation, persistent or significant disability,
congenital abnormality/birth defect of offspring, life-threatening
events or death.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2008, issue 3), MEDLINE
(1966 to July 2008) and EMBASE (1975 to July 2008) through
the Ovid platform (www.ovid.com), and CINAHL (1937 to July
2008) through EBSCOhost, using truncated variations of prepa-
ration names, including brand names, combined with truncated
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variations of terms related to osteoarthritis, all as text words. We
applied a validated methodological filter for controlled clinical tri-
als (Dickersin 1994). The specific search algorithms are displayed
in Appendix 1 for MEDLINE, EMBASE and CINAHL, and in
Appendix 2 for CENTRAL.
Searching other sources
Wemanually searched conference proceedings, used Science Cita-
tion Index to retrieve reports citing relevant articles, contacted con-
tent experts and trialists, and screened reference lists of all obtained
articles, including related reviews. Finally, we searched several
clinical trial registries ( www.clinicaltrials.gov, www.controlled-
trials.com, www.actr.org.au and www.umin.ac.jp/ ctr) to identify
ongoing trials. The last update of the search was performed on 28
July 2008.
Data collection and analysis
Selection of studies
Two review authors (EN and AR) independently evaluated all
yielded titles and abstracts for eligibility (see Figure 1). We re-
solved disagreements by consensus. No language restrictions were
applied. In case of multiple reports relating to the same trial, we
considered all reports.
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Figure 1. Flow chart
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Data extraction and management
Two review authors (EN and AR) extracted trial information in-
dependently using a standardised, piloted data extraction form ac-
companied by a codebook. We resolved disagreements by discus-
sion or by involvement of a third review author (SR or PJ). We
extracted generic and trade names of the experimental interven-
tion, the type of control used, dosage, frequency and duration of
treatment, patient characteristics (average age, gender, mean dura-
tion of symptoms, type of joints affected), type of pain- and func-
tion-related outcome extracted, trial design, trial size, duration of
follow-up, type and source of financial support, and publication
status from trial reports. When necessary, we approximated means
and measures of dispersion from figures in the reports. For cross-
over trials, we extracted data from the first period only because
of possible carry-over effects. Whenever possible, we used results
from an intention-to-treat analysis. If effect sizes could not be cal-
culated, we contacted the authors for additional data.
Assessment of risk of bias in included studies
Two review authors (EN and AR) independently assessed the ad-
equacy of randomisation, blinding and analyses (Juni 2001). We
resolved disagreements by consensus or discussion with a third
review author (SR or PJ). We assessed two components of ran-
domisation: generation of allocation sequences and concealment
of allocation. We considered generation of sequences adequate if
it resulted in an unpredictable allocation schedule; mechanisms
considered adequate included random-number tables, computer-
generated random numbers, minimisation, coin tossing, shuffling
cards and drawing lots. We considered concealment of alloca-
tion adequate if the investigators responsible for patient inclu-
sion were unable to suspect before allocation which treatment
was next; methods considered adequate include central randomi-
sation, pharmacy controlled randomisation using identical pre-
numbered containers, and sequentially numbered, sealed, opaque
envelopes. We considered blinding of the patients adequate if ex-
perimental and control preparations were explicitly described as
indistinguishable or if a double-dummy technique was used. We
considered blinding of therapists and outcome assessors adequate
if it was explicitly mentioned in the report that they were unaware
of the assigned treatment. If pain outcomes were patient-adminis-
tered, however, we considered patients to be the outcome assessors
and rated blinding of outcome assessors adequate if patients were
deemed adequately blinded as described above. We considered
analyses adequate if all randomised patients were included in the
analysis (intention-to-treat principle). Finally, we used GRADE
to describe the quality of the overall body of evidence (Guyatt
2008; Higgins 2008), defined as the extent of confidence in the
estimated treatment benefits and harms.
Data synthesis
We summarised continuous outcomes using differences in means
at the end of treatment across treatment groups. If some of the
required data were unavailable, we used approximations as previ-
ously described (Reichenbach 2007). We also expressed continu-
ous outcomes as effect sizes in standard deviation units, with the
differences in mean values at the end of follow-up across treatment
groups divided by the pooled standard deviation. An effect size of
-0.20 standard deviation units can be considered a small differ-
ence between experimental and control groups, a SMD of -0.50
a moderate difference, and -0.80 a large difference (Cohen 1988;
Juni 2006). We expressed binary outcomes as risk ratios (RR). We
performed analyses in RevMan version 5 (RevMan 2008). All P
values are two-sided.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
We retrieved 212 potentially relevant reports from our electronic
searches (Figure 1).We excluded a randomised placebo-controlled
trial of doxycycline in seronegative arthritis (Smieja 2001) and an
animal study that assessed the effects of oral doxycycline in dogs (
Brandt 1995). Six reports, describing one randomised controlled
trial, met our inclusion criteria (Brandt 2005).We did not find any
additional completed trials in conference proceedings, nor did we
identify relevant ongoing trials in trial registers. The included trial
was a multicentre, placebo-controlled trial in 431 obese women
with radiologically confirmed osteoarthritis of the knee. After a
single-blind placebo run-in of four weeks duration, which was
designed to allow the exclusionof patients unlikely to be compliant
with trial procedures, patients were randomly allocated to receive
100mg doxycycline or placebo twice a day for 30months. Patients
were permitted to take any pain medication throughout the trial.
Risk of bias in included studies
An overview of the methodological characteristics of the included
trial is presented in Figure 2. The trial was described as randomised
in blocks of six, although mechanisms to generate blocks of ran-
dom sequences and methods used to conceal allocation to treat-
ments were not specified. The trial was reported as double-blind
after a single-blind run-in period. We deemed blinding of patients
adequate in view of the use of a matching placebo. Patients were
explicitly described as blinded, whereas blinding of treating physi-
cians was not explicitly described. Analyses of clinical outcomes,
such as pain and function, were based on 307 patients who com-
pleted the 30-month treatment period asmandated in the protocol
(Brandt 2005). Analyses of radiological outcomes included all 361
patients who returned for their radiographic follow-up irrespective
of whether they discontinued the study drug. Safety analyses in-
cluded all 431 randomised patients according to the intention-to-
treat principle. The primary outcome of the trial was joint space
9Doxycycline for osteoarthritis of the knee or hip (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
narrowing on the semiflexed AP view in the tibiofemoral joint (
Buckland-Wright 1995). Measurements were done manually, ac-
cording to the method of Lequesne (Lequesne 1995), using the
points of a screw-adjustable compass and a graduated magnifying
lens. Measurements were made by an observer who was blinded
to the treatment group assignment of the subject. The intra- and
inter-reader reproducibilities of repeated measurements of joint
space width in a random sample of 30 radiographs (on which all
identifying informationwasmasked)were excellent (intraclass cor-
relation coefficients of 0.99 and 0.96, respectively). Assessors de-
termining the joint space width were not blinded to the sequence
of the radiographs. No sample size calculation was described. The
trial was supported in part by the National Institute of Health
(NIH); no commercial funding was reported. For the effective-
ness outcomes, we classified the quality of the evidence (Guyatt
2008) as low to moderate, because only a single trial was available,
estimates were not derived from intention-to-treat analyses, and
were imprecise for pain and function (see ’Summary of findings
for the main comparison’). For withdrawals due to adverse events
and serious adverse event outcomes, we classified the quality of
the evidence (Guyatt 2008) as low to moderate in view of a single
available trial and an imprecise estimate for serious adverse events
(see ’Summary of findings for the main comparison’).
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Figure 2. Methodological characteristics and source of funding of the included trial. (+) indicates low risk of
bias, (?) unclear and (-) a high risk of bias on a specific item.
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Effects of interventions
See: Summary of findings for the main comparison
Data on clinical outcomes at the end of treatment were provided
by the investigators in personal communications. Pain in the index
knee was measured after a 50-foot walk on a 10 cm visual analogue
scale (VAS) (Brandt 2005). The analysis revealed a difference in
means between doxycycline and placebo of -0.20 cm (95% CI -
0.77 to 0.37 cm, P = 0.49, Figure 3). The Likert version of the
WOMAC function subscale was used to measure disability after
30 months (range 17 to 85), with a mean difference of -1.10
(95% CI -3.86 to 1.66, P = 0.44, Figure 4). These differences
correspond to clinically irrelevant effect sizes of -0.08 and -0.09
standard deviation units for pain and function, respectively. The
difference in changes in minimum joint space narrowing was in
favour of doxycycline (-0.15 mm, 95% CI -0.28 to -0.02 mm, P
= 0.03, Figure 5), which corresponds to a small effect size of -0.23
standard deviation units.
Figure 3. Forest plot of 1 trial comparing the effects of doxycycline and placebo on knee pain. Values on x-
axis denote mean differences in 50-foot walking pain as measured on a 10-cm VAS scale.
Figure 4. Forest plot of 1 trial comparing the effects of doxycycline and placebo on physical function. Values
on x-axis denote mean differences in WOMAC disability scores.
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Figure 5. Forest plot of 1 trial comparing the effects of doxycycline and placebo on physical function. Values
on x-axis denote mean differences in minimum joint space width in mm.
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During the 30 months of treatment, patients were more likely to
withdraw due to adverse events in the doxycycline group com-
pared to the placebo group (RR 1.69, 95% CI 1.03 to 2.75, P =
0.04, Figure 6). Data on serious adverse events were provided by
investigators in personal communications. The authors found 31
patients with serious adverse events in the doxycyline group and
29 in the placebo group (RR 1.04, 95% CI 0.65 to 1.67, P = 0.86,
Figure 7). None of these events were fatal and none of the serious
adverse events were deemed to be related to doxycycline (Brandt
2005).
Figure 6. Forest plot of 1 trial comparing patients withdrawn or dropped out because of adverse events
between doxycycline and placebo. Values on x-axis denote risk ratios.
Figure 7. Forest plot of 1 trial comparing patients experiencing any serious adverse event between
doxycycline and placebo. Values on x-axis denote risk ratios.
D I S C U S S I O N
Summary of main results
Our systematic review indicates that the symptomatic benefit of
doxycycline in patientswith osteoarthritis of the knee isminimal to
non-existent. The small benefit in terms of joint space narrowing is
of questionable clinical relevance. The higher risk of drop-outs due
to adverse events in the doxycycline group compared to placebo
indicates that this benefit is outweighed by safety problems.
Quality of the evidence
The evidence is based on a single available randomised trial includ-
ing only obese women with mild to moderate osteoarthritis of the
knee (Brandt 2005). The trial was designed to detect differences in
joint space narrowing rather than differences in clinical outcomes.
No threshold for the level of knee pain was used for inclusion and
the average level of knee pain was low at baseline, leaving little
room for improvement. Radiological and clinical outcomes corre-
late poorly in patients with osteoarthritis and it is not surprising
that effects of doxycycline differ for these outcomes. Joint space
width in millimetres evaluated on radiographs is currently consid-
ered to be the preferred technique to evaluate structural progres-
sion in osteoarthritis, and is required by the regulatory agencies
(Hellio 2009). The use of semiflexed radiographs instead of AP
views improves detection of tibiofemoral joint space narrowing,
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especially in early osteoarthritis (Merle-Vincent 2007). However,
there is a debate about how to define relevant radiographic pro-
gression, and a recently published OARSI-OMERACT initiative
recommends dichotomising the continuous variable of joint space
narrowing to distinguish between progressors and non-progres-
sors, based on the absolute change in joint space width over a
predefined threshold (Ornetti 2009). Mazzuca et al. reported that
doxycycline did not differ from placebo in the frequency of rele-
vant joint space loss using a range of different cut-offs to distin-
guish between the presence or absence of relevant joint space loss
(≥ 0.5 mm, ≥ 1.0 mm, ≥ 20%, or ≥ 50% of joint space width
at baseline, Mazzuca 2006). No evidence is available for patients
representing a broader spectrum of osteoarthritis, includingmales,
patients with hip osteoarthritis and non-obese patients. The avail-
able trial is potentially biased: it remains unclear whether sequence
generation and allocation concealment were adequate and a high
number of patients were excluded from analyses, which may result
in overestimation of benefits (Nuesch 2009).
Potential biases in the review process
We based our review on a broad literature search and it seems
unlikely that we missed relevant trials (Egger 2003). Two review
authors performed selection of trials and data extraction inde-
pendently to minimise bias and transcription errors (Egger 2001;
Gøtzsche 2007). Aswith any systematic review, our study is limited
by the quality of the available evidence. As indicated above, only
one trial was available and this trial suffered from some method-
ological shortcomings. Therefore, this systematic review is incon-
clusive (Nuesch 2009a). The observed effects, both beneficial and
harmful, would need to be confirmed in at least one indepen-
dent, methodologically sound trial in a wider spectrum of patients
with symptomatic osteoarthritis before definite conclusions can
be drawn.
Agreements and disagreements with other
studies or reviews
Doxycycline may reduce the progression of cartilage degeneration
in canine osteoarthritis through inhibition of cartilagematrix met-
allo-proteinases (Brandt 1995; Yu 1992). Similar results were ob-
tained in guinea pigs (Greenwald 1994) and rabbits (Golub 1993).
In a canine osteoarthritis model, doxycycline reduced disease pro-
gression (Yu 1992). This notion supports the observed reduction
in joint space narrowing in the randomised trial in humans (Brandt
2005). When studied in patients with chronic seronegative arthri-
tis (Smieja 2001), doxycyline had no effect on pain reduction or
function improvement compared to placebo after three months of
treatment. The trial included in our review included patients with
non-inflammatory symptomatic osteoarthritis and used a longer
treatment duration of 30 months, but results were similar (Brandt
2005).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The symptomatic benefit of doxycycline is minimal to non-exis-
tent, while the small benefit in terms of joint space narrowing is
of questionable clinical relevance and outweighed by safety prob-
lems. Doxycycline should therefore not be recommended for the
treatment of osteoarthritis of the knee or hip.
Implications for research
The available evidence of the effectiveness of doxycycline is based
on a single randomised trial. An additional placebo-controlled trial
would be needed before firm conclusions can be drawn. This trial
should be appropriately powered, use adequate mechanisms to
conceal allocation and include all patients in the analyses according
to the intention-to-treat principle. The trial should include a broad
spectrum of patients, including males and non-obese individuals.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brandt 2005
Methods Randomised controlled trial with 2 parallel groups
Randomisation stratified by centre
Trial duration: 30 months
Multicentre trial including 6 centres
No power calculation reported
Participants 431 patients with radiologically confirmed knee osteoarthritis were randomised
Number of females: 431 (100%)
Average age: 54.9 years
Average BMI: 36.7 kg/m2
Severity of knee osteoarthritis: 59% with Kellgren/Lawrence grade 2 and 41% with
Kellgren/Lawrence grade 3
Interventions Experimental intervention: doxycycline, 100 mg twice daily
Control intervention: placebo, twice daily
Treatment duration: 30 months
Analgesics other than study drugs allowed and intake was similar between groups
Outcomes Extracted pain outcome: 50-foot walking pain after 30 months
Extracted function outcome: WOMAC disability subscore after 30 months
Primary outcome: joint space narrowing in the tibiofemoral compartment
Notes -
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Subjects (...) were randomly assigned”
Comment: no mention of the mechanism used for sequence
generation
Allocation concealment? Unclear Quote: “Patients were allocated randomly to treatment groups
in blocks of 6”
Comment: no mention of concealment of allocation
Blinding of patients described? Yes Comment: indistinguishable interventions and the description
of a double-blind phase implies blinding of patients
Blinding of physicians? Yes Comment: clearly distinguished between single blind run-in pe-
riod and double-blind phase. Blinding of physicians probable
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Brandt 2005 (Continued)
Blinding of outcome assessors? Yes Comment: depending on the outcome, patients or physicians
were the assessors, both of which were blinded
Interventions reported as indistinguish-
able?
Yes Quote: “matched placebo”
Intention-to-treat analysis?
All outcomes
No 69 of 218 patients (32%) excluded in experimental group and
55 of 213 patients (26%) excluded in control group
Funding by commercial body avoided? Unclear No information provided
Funding by non-profit organisation? Yes Quote: “Supported by the NIH (grants R01-AR-43348, P60-
AR-20582, and R01-AR-44370)”
BMI = body mass index
Characteristics of excluded studies [ordered by year of study]
Brandt 1995 Animal study
Smieja 2001 No patients in osteoarthritis
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D A T A A N D A N A L Y S E S
Comparison 1. Doxycycline versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 1 307 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.77, 0.37]
2 Physical function 1 307 Mean Difference (IV, Fixed, 95% CI) -1.10 [-3.86, 1.66]
3 Minimum joint space width 1 361 Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.28, -0.02]
4 Number of patients withdrawn
due to adverse events
1 431 Risk Ratio (IV, Fixed, 95% CI) 1.69 [1.03, 2.75]
5 Number of patients experiencing
any serious adverse events
1 431 Risk Ratio (IV, Fixed, 95% CI) 1.04 [0.65, 1.67]
Analysis 1.1. Comparison 1 Doxycycline versus placebo, Outcome 1 Pain.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 1 Pain
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
Brandt 2005 149 2 (2.6) 158 2.2 (2.5) 100.0 % -0.20 [ -0.77, 0.37 ]
Total (95% CI) 149 158 100.0 % -0.20 [ -0.77, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
-2 -1 0 1 2
Favours doxycycline Favours placebo
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Analysis 1.2. Comparison 1 Doxycycline versus placebo, Outcome 2 Physical function.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 2 Physical function
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brandt 2005 149 36.3 (11.6) 158 37.4 (13.1) 100.0 % -1.10 [ -3.86, 1.66 ]
Total (95% CI) 149 158 100.0 % -1.10 [ -3.86, 1.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
-4 -2 0 2 4
Favours doxycycline Favours placebo
Analysis 1.3. Comparison 1 Doxycycline versus placebo, Outcome 3 Minimum joint space width.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 3 Minimum joint space width
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
N Mean(SD)[mm] N Mean(SD)[mm] IV,Fixed,95% CI IV,Fixed,95% CI
Brandt 2005 181 0.3 (0.6) 180 0.45 (0.7) 100.0 % -0.15 [ -0.28, -0.02 ]
Total (95% CI) 181 180 100.0 % -0.15 [ -0.28, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
-1 -0.5 0 0.5 1
Favours doxycycline Favours placebo
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Analysis 1.4. Comparison 1 Doxycycline versus placebo, Outcome 4 Number of patients withdrawn due to
adverse events.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 4 Number of patients withdrawn due to adverse events
Study or subgroup Doxycycline Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Brandt 2005 38/218 22/213 100.0 % 1.69 [ 1.03, 2.75 ]
Total (95% CI) 218 213 100.0 % 1.69 [ 1.03, 2.75 ]
Total events: 38 (Doxycycline), 22 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.036)
0.2 0.5 1 2 5
Favours doxcycline Favours placebo
Analysis 1.5. Comparison 1 Doxycycline versus placebo, Outcome 5 Number of patients experiencing any
serious adverse events.
Review: Doxycycline for osteoarthritis of the knee or hip
Comparison: 1 Doxycycline versus placebo
Outcome: 5 Number of patients experiencing any serious adverse events
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Brandt 2005 31/218 29/213 100.0 % 1.04 [ 0.65, 1.67 ]
Total (95% CI) 218 213 100.0 % 1.04 [ 0.65, 1.67 ]
Total events: 31 (Experimental), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
0.2 0.5 1 2 5
Favours doxycycline Favours placebo
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A P P E N D I C E S
Appendix 1. MEDLINE, EMBASE and CINAHL search strategy
OVID MEDLINE OVID EMBASE CINAHL through EBSCOhost
Search terms for design
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trial.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single blind method.sh.
7. clinical trial.pt.
8. exp clinical trial/
9. (clin$ adj25 trial$).ti,ab.
10. ((singl$ or doubl$ or trebl$ or tripl$)
adj25 (blind$ or mask$)).ti,ab.
11. placebos.sh.
12. placebo$.ti,ab.
13. random$.ti,ab.
14. research design.sh.
15. comparative study.sh.
16. exp evaluation studies/
17. follow up studies.sh.
18. prospective studies.sh.
19. (control$ or prospectiv$ or volun-
teer$).ti,ab.
Search terms for design
1. randomized controlled trial.sh.
2. randomization.sh.
3. double blind procedure.sh.
4. single blind procedure.sh.
5. exp clinical trials/
6. (clin$ adj25 trial$).ti,ab.
7. ((singl$ or doubl$ or trebl$ or tripl$)
adj25 (blind$ or mask$)).ti,ab.
8. placebo.sh.
9. placebo$.ti,ab.
10. random$.ti,ab.
11. methodology.sh.
12. comparative study.sh.
13. exp evaluation studies/
14. follow up.sh.
15. prospective study.sh.
16. (control$ or prospectiv$ or volun-
teer$).ti,ab.
Search terms for design
1. (MH “Clinical Trials+”)
2. (MH “Random Assignment”)
3. (MH “Double-Blind Studies”) or (MH
“Single-Blind Studies”)
4. TX (clin$ n25 trial$)
5. TX (sing$ n25 blind$)
6. TX (sing$ n25 mask$)
7. TX (doubl$ n25 blind$)
8. TX (doubl$ n25 mask$)
9. TX (trebl$ n25 blind$)
10. TX (trebl$ n25 mask$)
11. TX (tripl$ n25 blind$)
12. TX (tripl$ n25 mask$)
13. (MH “Placebos”)
14. TX placebo$
15. TX random$
16. (MH “Study Design+”)
17. (MH “Comparative Studies”)
18. (MH “Evaluation Research”)
19. (MH “Prospective Studies+”)
20. TX (control$ or prospectiv$ or volun-
teer$)
21. S1 or S2 or (…….) or S20
Search terms for Osteoarthritis
20. exp osteoarthritis/
21. osteoarthriti$.ti,ab,sh.
22. osteoarthro$.ti,ab,sh.
23. gonarthriti$.ti,ab,sh.
24. gonarthro$.ti,ab,sh.
25. coxarthriti$.ti,ab,sh.
26. coxarthro$.ti,ab,sh.
27. arthros$.ti,ab.
28. arthrot$.ti,ab.
29. ((knee$ or hip$ or joint$) adj3 (pain$
or ach$ or discomfort$)).ti,ab.
30. ((knee$ or hip$ or joint$) adj3
stiff$).ti,ab.
Search terms for Osteoarthritis
17. exp osteoarthritis/
18. osteoarthriti$.ti,ab,sh.
19. osteoarthro$.ti,ab,sh.
20. gonarthriti$.ti,ab,sh.
21. gonarthro$.ti,ab,sh.
22. coxarthriti$.ti,ab,sh.
23. coxarthro$.ti,ab,sh.
24. arthros$.ti,ab.
25. arthrot$.ti,ab.
26. ((knee$ or hip$ or joint$) adj3 (pain$
or ach$ or discomfort$)).ti,ab.
27. ((knee$ or hip$ or joint$) adj3
stiff$).ti,ab.
Search terms for Osteoarthritis
22. osteoarthriti$
23. (MH “Osteoarthritis”)
24. TX osteoarthro$
25. TX gonarthriti$
26. TX gonarthro$
27. TX coxarthriti$
28. TX coxarthro$
29. TX arthros$
30. TX arthrot$
31. TX knee$ n3 pain$
32. TX hip$ n3 pain$
33. TX joint$ n3 pain$
34. TX knee$ n3 ach$
35. TX hip$ n3 ach$
36. TX joint$ n3 ach$
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(Continued)
37. TX knee$ n3 discomfort$
38. TX hip$ n3 discomfort$
39. TX joint$ n3 discomfort$
40. TX knee$ n3 stiff$
41. TX hip$ n3 stiff$
42. TX joint$ n3 stiff$
43. S22 or S23 or S24….or S42
Search terms for Doxycycline
31. exp doxycycline/
32. doxycycline.tw.
33. deoxyoxytetracycline.tw.
34. hydramycin.tw.
35. vibramycin.tw.
36. vibravenos.tw.
37. oracea.tw.
38. adoxa.tw.
39. doryx.tw.
40. doxy$.tw.
41. monodox$.tw.
42. periostat.tw.
43. atridox.tw.
44. vibrox$.tw.
Search terms for Doxycycline
28. exp doxycycline/
29. doxycycline.tw.
30. deoxyoxytetracycline.tw.
31. hydramycin.tw.
32. vibramycin.tw.
33. vibravenos.tw.
34. oracea.tw.
35. adoxa.tw.
36. doryx.tw.
37. doxy$.tw.
38. monodox$.tw.
39. periostat.tw.
40. atridox.tw.
41. vibrox$.tw.
Search terms for Doxycycline
44. (MH “ Doxycycline ”)
45. TX doxycycline
46. TX deoxyoxytetracycline
47. TX hydramycin
48. TX vibramycin
49. TX vibravenos
50. TX oracea
51. TX adoxa
52. TX doryx
53. TX doxy$
54. TX monodox$
55. TX periostat
56. TX atridox
57. TX vibrox$
58. S44 or S45 or …. S57
Combining terms
45. or/1-19
46. or/20-30
47. or/31-44
48. and/45-47
49. animal/
50. animal/ and human/
51. 49 not 50
52. 48 not 51
53. remove duplicates from 52
Combining terms
42. or/1-16
43. or/17-27
44. or/28-41
45. and/42-44
46. animal/
47. animal/ and human/
48. 46 not 47
49. 45 not 48
50. remove duplicates from 49
Combining terms
59. S21 and S43 and S58
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Appendix 2. CENTRAL search strategy
CENTRAL
Search terms for osteoarthritis
#1. MeSH descriptor Osteoarthritis explode all trees
#2. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro*
OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR
((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discomfort*))
OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials
Search terms for doxycycline
#3. MeSH descriptor Doxycycline explode all trees
#4. doxycycline in Clinical Trials
#5. deoxyoxytetracycline in Clinical Trials
#6. hydramycin in Clinical Trials
#7. vibramycin in Clinical Trials
#8. vibravenos in Clinical Trials
#9. oracea in Clinical Trials
#10. adoxa in Clinical Trials
#11. doryx in Clinical Trials
#12. doxy* in Clinical Trials
#13. monodox* in Clinical Trials
#14. periostat in Clinical Trials
#15. atridox in Clinical Trials
#16. vibrox* in Clinical Trials
Combining terms
#17. (#1 OR #2)
#18. (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)
#19. (#17 AND #18) in Clinical Trials
WH A T ’ S N E W
Last assessed as up-to-date: 10 January 2009.
1 May 2008 Amended CMSG ID C118-R
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Because only one study was included in our review, we used inverse variance fixed-effect model instead of the random-effects model of
meta-analysis, and we did not perform the stratified analyses. Differences between experimental and control groups were expressed as
mean differences instead of standardised mean differences due to better interpretability of the results. We could not perform stratified
analyses or funnel plot evaluation to investigate whether potential variation between trials could be explained by biases affecting
individual trials or by publication bias.
26Doxycycline for osteoarthritis of the knee or hip (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
